Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10723654 | 0.82 | PRKCZ (0.44) | FLT3KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL27630956 | 0.81 | TEK (0.46) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL3270464 | 0.80 | ALDH1A1 (0.42) | KMT2AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5960135 | 0.79 | ALDH1A1 (0.41) | KMT2AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL411972 | 0.77 | KDM4E (0.36) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL1890032 | 0.76 | PPARG (0.56) | FLT3RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6467375 | 0.76 | MAPK13 (0.62) | CDK4CCND1KMT2AKDM4EALDH1A1 | |
| SCHEMBL701773 | 0.75 | XDH (0.49) | KMT2ARAB9AKDM4ELMNAMAPT | |
| SCHEMBL411590 | 0.74 | MAPT (0.44) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL411571 | 0.74 | KMT2A (0.44) | KMT2ARAB9AKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| CN-1771050-A | macrocyclic inhibitors of hepatitis c serine protease | ENANTA PHARM INC (US) | 2006-05-10 | — | — | CN | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | CDK4 184/4885CCND1 446/4885FLT3 1630/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | CDK4 184/4885CCND1 434/4885FLT3 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.